PE20241617A1 - Composiciones que contienen adenosin trifosfato (atp) y metodos de uso para la funcion cognitiva - Google Patents

Composiciones que contienen adenosin trifosfato (atp) y metodos de uso para la funcion cognitiva

Info

Publication number
PE20241617A1
PE20241617A1 PE2023003445A PE2023003445A PE20241617A1 PE 20241617 A1 PE20241617 A1 PE 20241617A1 PE 2023003445 A PE2023003445 A PE 2023003445A PE 2023003445 A PE2023003445 A PE 2023003445A PE 20241617 A1 PE20241617 A1 PE 20241617A1
Authority
PE
Peru
Prior art keywords
atp
methods
cognitive function
compositions containing
adenosine triphosphate
Prior art date
Application number
PE2023003445A
Other languages
English (en)
Spanish (es)
Inventor
John Rathmacher
Larry Kolb
Shawn Baier
Original Assignee
Tsi Usa Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsi Usa Llc filed Critical Tsi Usa Llc
Publication of PE20241617A1 publication Critical patent/PE20241617A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PE2023003445A 2021-06-22 2022-06-22 Composiciones que contienen adenosin trifosfato (atp) y metodos de uso para la funcion cognitiva PE20241617A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163213378P 2021-06-22 2021-06-22
PCT/US2022/034510 WO2022271813A1 (en) 2021-06-22 2022-06-22 Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function

Publications (1)

Publication Number Publication Date
PE20241617A1 true PE20241617A1 (es) 2024-08-07

Family

ID=84544774

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023003445A PE20241617A1 (es) 2021-06-22 2022-06-22 Composiciones que contienen adenosin trifosfato (atp) y metodos de uso para la funcion cognitiva

Country Status (12)

Country Link
US (1) US20240299435A1 (https=)
EP (1) EP4358972A4 (https=)
JP (1) JP2024524288A (https=)
CN (1) CN117835985A (https=)
AU (1) AU2022297444A1 (https=)
CA (1) CA3224861A1 (https=)
CL (1) CL2023003882A1 (https=)
CO (1) CO2024000517A2 (https=)
EC (1) ECSP24004256A (https=)
MX (1) MX2024000145A (https=)
PE (1) PE20241617A1 (https=)
WO (1) WO2022271813A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
US20050261239A1 (en) * 2004-05-23 2005-11-24 Universiteit Van Maastricht Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue
WO2008001494A1 (en) * 2006-06-27 2008-01-03 Kowa Co., Ltd. Pharmaceutical agent for prevention of fatigue and/or recovery from fatigue
US9522161B2 (en) * 2010-10-26 2016-12-20 Advanced Bio Development, Inc. Performance enhancing composition and method of delivering nutrients
PH12022550598A1 (en) * 2010-12-23 2024-03-11 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
US20140044690A1 (en) * 2012-08-08 2014-02-13 University Of South Florida High-Energy Compounds for Use in Alzheimer's and Other Neurodegenerative Diseases
US10092590B2 (en) * 2012-09-10 2018-10-09 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
WO2014106860A2 (en) * 2013-01-03 2014-07-10 Laila Nutraceuticals Synergistic dietary supplement compositions for enhancing physical performance and energy levels
US10888576B2 (en) * 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
BR112022004108A2 (pt) * 2019-09-05 2022-05-31 Tsi Group Ltd Métodos para aprimorar a absorção gastrointestinal e utilização sistêmica de materiais nutricionais, para aumentar a biodisponibilidade de um material nutricional em um animal e para aprimorar a absorção de um material nutricional em ser humano

Also Published As

Publication number Publication date
JP2024524288A (ja) 2024-07-05
CN117835985A (zh) 2024-04-05
WO2022271813A1 (en) 2022-12-29
EP4358972A4 (en) 2025-04-16
CA3224861A1 (en) 2022-12-29
CO2024000517A2 (es) 2024-05-10
AU2022297444A1 (en) 2024-01-18
CL2023003882A1 (es) 2024-07-05
MX2024000145A (es) 2024-03-22
EP4358972A1 (en) 2024-05-01
ECSP24004256A (es) 2024-02-29
US20240299435A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
CO2025009073A2 (es) Compuestos cíclicos fusionados y uso de los mismos
GT199900119A (es) Jarabe antihistaminico estabilizado.
CR8402A (es) Indazol-o-glucosidos sustitutos
ES2112377T3 (es) Procedimiento para la preparacion de derivados del taxano y productos intermedios.
ES2141913T3 (es) Agonistas y antagonistas de los receptores de la adenosina a1.
EA200200770A1 (ru) Производные пурина
ES2051772T3 (es) 2-sustituido-e-fusionado-(1,2,4)-triazol(1,5-c)pirimidinas, composiciones farmaceuticas y sus usos.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ES2059491T3 (es) Derivados de indol con anillos condensados.
CY1111843T1 (el) 2-υποκατεστημενα αναλογα βιταμινης d και θεραπευτικες χρησεις αυτων
ES2166504T3 (es) Compuestos de nitrogeno acilados que pueden ser utilizados como aditivos para un aceite lubricante y en composiciones combustibles.
HN2008001934A (es) 18-metil-19-nor-androst-4-en-17,17-espiroesteres (18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen.
PE20241617A1 (es) Composiciones que contienen adenosin trifosfato (atp) y metodos de uso para la funcion cognitiva
UY38332A (es) Activadores de la vía inducible del gen "rig-i" del ácido retinoico y métodos de uso de los mismos
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
ES2056184T3 (es) Derivados del 2-amino-6-cloro-4-nitro-fenol, procedimientos para su preparacion y colorantes para el cabello que contienen dichos derivados como colorantes nitrados directos.
ES2039200T3 (es) Derivados isotiazolonicos.
ES2074505T3 (es) Pomada que contiene propionato de deprodona.
ES8801622A1 (es) Un procedimiento para preparar derivados arilicos de dienamidas
AR033702A1 (es) Compuestos triciclicos utiles como inhibidores de la transcriptasa inversa del vih
ES2058150T3 (es) Procedimiento para la obtencion de productos de reaccion del 2,2-bis(4-hidroxifenil)hexafluorpropano asi como estos nuevos derivados.
ES2192495B1 (es) Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
AR134453A1 (es) Inhibidores de cbl-b y métodos de uso de los mismos
AR021577A1 (es) Preparado con una amplitud terapeutica mejorada, que contiene inhibidores de la sintesis de los nucleotidos
ES2066905T3 (es) Heterociclos substituidos con amino como inhibidores de renina.